If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
176
results.
Updated on
05/11/2025 [07:41:00]
Results 50 to 75 of 176
Absstract of: WO2025177282A1
A system for predicting a response to nutritional therapy for treating Crohn's Disease (CD), including a computer with a processor and memory, a machine learning module, wherein the machine learning module is programed to train a model by accepting a training data set comprising multiomics data of subjects with Crohn's disease that were treated by exclusive enteral nutrition (EEN) and a determination if each subject was a responder that successfully responded to the treatment or was a non-responder that unsuccessfully responded to the treatment, and wherein the machine learning module uses the trained model to accept multiomics data of a patient and predict if the patient is a responder or a non-responder.
Absstract of: EP4606910A1
The present invention relates to diagnostic and prognostic methods and their use in diagnosing or predicting disease progression in a subject with Ulcerative Colitis (UC). More particularly, the present invention relates to a gene expression signature and the use thereof in determining the likelihood of progression of Ulcerative Colitis in a subject, as well as compositions for the detection thereof. The invention also extends to the use of biomarkers as targets to improve the treatment of Ulcerative Colitis in patients.
Absstract of: EP4607197A1
Provided is an examination method for irAE enteritis, said examination method comprising a detection step for detecting, as an indicator of ulcerous colitis-like irAE enteritis, an antibody that immunologically reacts with a fragment of, or the entirety of, integrin αvβ6 in a specimen.
Absstract of: AU2023364180A1
Provided herein is a peptide array comprising a plurality of flagellin peptides corresponding to highly conserved peptide regions. For example, the peptide array comprises a plurality of
Absstract of: CN120536298A
The invention belongs to the technical field of microorganisms, and discloses lactobacillus fermentum (L.f) LFSJ001 and application of the lactobacillus fermentum (L.f) LFSJ001 in preparation of a product for preventing or treating ulcerative colitis. The lactobacillus fermentum LFSJ001 is subjected to autonomous separation and identification. According to the application disclosed by the invention, a mouse colitis model is constructed by using DSS, and it is found that combined treatment of lactobacillus fermentum LFSJ001 and mesalazine (5-ASA) can enhance improvement of 5-ASA on colitis symptoms, including a plurality of indexes such as a disease activity index, a colon injury index and a spleen index. Therefore, the lactobacillus fermentum LFSJ001 can be used as a combined medicine of the 5-ASA, the medicine effect of the 5-ASA is enhanced, the occurrence and development of the ulcerative colitis are inhibited, the intestinal barrier is improved, and a new diagnosis and treatment direction and strategy are provided for prevention and treatment of the ulcerative colitis.
Absstract of: CN120536347A
The invention discloses a preparation method of an intestinal organ inflammation model based on inflammatory factors, and belongs to the technical field of biomedicine. The invention provides an innovative in-vitro culture method based on intestinal organs, and aims to simulate inflammatory response in inflammatory bowel disease (IBD) and influence of the inflammatory response on intestinal epithelium and stem cells. Specific inflammatory factors IL-22, IFN-gamma and TNF-alpha are introduced into an organoid culture system, an inflammatory environment related to IBD is successfully induced, and a key feature of IBD is observed: expression of a fetal-like intestine stem cell marker gene Sca-1 is remarkably increased. The model fully simulates the repair mechanism of the intestinal tract in inflammatory response. The invention discloses key effects of different inflammatory factors on intestinal epithelium functions and fetal-like intestine stem cells in a repair process, and provides a unique in-vitro platform for deeply researching a repair mechanism. The invention provides a novel in-vitro experimental platform for mechanism research, diagnosis, personalized treatment and drug screening of the inflammatory bowel disease.
Absstract of: CN120519578A
The invention provides an application of APOL1 in diagnosis of neonatal necrotizing enterocolitis. Research finds that compared with a control child patient, the APOL1 gene and protein expression level in NEC child patients are remarkably improved for the first time, ROC curve analysis results show that when APOL1 is used for NEC diagnosis, AUC is 0.86, and diagnosis accuracy is high. Therefore, the APOL1 can be used as a specific diagnostic marker of the NEC for assisting clinical diagnosis of the NEC. Furthermore, when the APOL1 is combined with C reactive protein, lymphocyte count (LYM) or hemoglobin level to be used for NEC diagnosis, AUC can be further improved to 0.91-0.94, and the diagnosis accuracy is further improved. The invention provides a novel specific biomarker for diagnosis of NEC, and has important clinical value for early diagnosis and early treatment of NEC.
Absstract of: US2025262251A1
Provided are methods for treating an individual who has inflammatory bowel diseases (IBD and) spondyloarthritis by selecting the individual based on a determination that that the gastrointestinal system of the individual comprises a microbiome lacking bacteria that provide functional folate trap, and administering to the individual sulfasalazine and bacteria that include a functional folate trap to thereby treat the IBD.
Absstract of: AU2024230939A1
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Absstract of: WO2025172923A1
The present disclosure relates to a system (102) and a method (300) for personalized health management to provide recommendations for a user diagnosed with IBS and related symptoms. The method (300) includes receiving (302) user datasets, determining (304) a current IBS symptom score, and computing (306) a target IBS symptom score. A personalized plan is recommended, initiating (308) a gut cleansing phase to arrive at a first IBS symptom score and assessing (310) and revising the plan for a reintroduction phase to determine a second IBS symptom score. Further, assessing (312) identifies symptom triggers, refining the plan to arrive at a third IBS symptom score. At a sustenance phase, assessing (314) determines long-term impacts and revises the plan to maintain the target IBS symptom score. Therefore, the present disclosure provides a data-driven, adaptive system for dynamic IBS management, ensuring sustained improvement and symptom control.
Absstract of: CN120496800A
The invention relates to the technical field of disease diagnosis, in particular to an inflammatory bowel disease pathological slice diagnosis method based on a link algorithm, which comprises the following steps: S1, acquiring an inflammatory bowel disease pathological slice; s2, creating a link algorithm; s3, training the link algorithm in the S2 by using the pathological slice of the inflammatory bowel disease obtained in the S1 to obtain an optimal link algorithm; and S4, inputting pathological slices of the inflammatory bowel disease into the optimal link algorithm in the S3, so as to output diagnosis results of the pathological slices of the inflammatory bowel disease, and enabling the diagnosis results of the plurality of pathological slices of the inflammatory bowel disease to form a report to be exported. According to the method, the link algorithm is established, and the microscopic features of a large number of samples are counted, so that a doctor is assisted in finding potential biomarkers and pathological typing rules of the inflammatory bowel disease, objective quantitative indexes can be provided, subjective deviation of manual interpretation can be reduced, and the consistency of ulcerative colitis diagnosis results can be improved.
Absstract of: WO2025171261A1
Compounds are described herein for the detection of the activity of an enzyme. The compounds include a recognition domain/substrate structured to interact with the enzyme, a reporter molecule, and a linking group forming a covalent bond between the recognition domain and reporter molecule. Upon interaction of the recognition domain with the enzyme, the covalent bond is destroyed, rendering reporter molecule detectable by a chemical detection device. Methods of detecting enzymatic activity of a plurality of enzymes are also described herein. Such methods include reacting a compound (having a recognition domain/substrate structured to interact with the enzyme, a reporter molecule, and a linking group forming a covalent bond between the recognition domain and reporter molecule) with an enzyme, and identifying detectable reporter molecules with a chemical detection device.
Absstract of: US2025255558A1
Systems and methods are disclosed for diagnosis, risk assessment, and/or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel.
Absstract of: US2025258170A1
A protein comprising an amino acid sequence according to SEQ ID NO: 1, wherein the amino acid in position 4 of SEQ ID NO: 1 is selected from the group consisting of N, S, R, T and I, preferably consisting of N, S and R and wherein the amino acid in position 5 of SEQ ID NO: 1 is selected from the group consisting of R, V, L, F, M, I, H, S, T, A, P and G, with the proviso that the amino acid sequence is not SEQ ID NO: 24.
Absstract of: AU2024224464A1
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/or diagnostic use in a subgroup of patients having ulcerative colitis.
Absstract of: MX2020002643A
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Absstract of: CN120446472A
The invention relates to the technical field of biology, discloses a method for predicting and evaluating inflammatory bowel disease fibrosis through prostacyclin detection, and particularly relates to a serological biomarker for predicting and evaluating inflammatory bowel disease fibrosis and application of the serological biomarker. According to the method for predicting and evaluating inflammatory bowel disease fibrosis through prostacyclin detection, as a biomarker of inflammatory bowel disease fibrosis, PGI2 in serum can be used for preparing reagents and/or drugs for auxiliary diagnosis, curative effect evaluation and relapse monitoring of inflammatory bowel disease fibrosis, the effect is remarkable, and the specificity is good. The reagent is preferably an ELISA diagnostic kit. The invention also discloses a method for predicting and evaluating the fibrosis truncation value of the inflammatory bowel disease by using the biomarker and a method for predicting and evaluating the fibrosis truncation value of the inflammatory bowel disease by using the biomarker.
Absstract of: CN120452749A
The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.
Absstract of: WO2025163643A1
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
Absstract of: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Absstract of: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Absstract of: US2025249050A1
The invention relates to core components from five strains of independently isolated, identified and patent-deposited probiotics and fermentation metabolites thereof (postbiotics), as well as their use as a protector in alleviating dextran sulfate sodium (DSS) induced-colitis in mice. Further disclosed the mechanism of the probiotics and fermentation metabolites thereof (postbiotics) to alleviate colitis in mice.
Absstract of: JP2024015204A
To provide peptides, compositions and methods for treating gastrointestinal disorders.SOLUTION: The invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.SELECTED DRAWING: None
Absstract of: CN116514983A
The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody and application thereof. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano antibody sequence, and finally separating to obtain three nano antibodies which are respectively named A2, A6 and H10. The three nano antibodies have different antigen complementarity determining regions, SPR results show that the three nano antibodies all show high-affinity binding with human DR3 extracellular domains, and the nano antibodies provided by the invention are expected to provide experimental factual basis for treatment thinking of DR3-related diseases.
Nº publicación: CN120392795A 01/08/2025
Applicant:
SHENZHEN INSTITUTES OF ADVANCED TECH
SHENZHEN UNIV OF TECHNOLOGY
\u6DF1\u5733\u5148\u8FDB\u6280\u672F\u7814\u7A76\u9662,
\u6DF1\u5733\u7406\u5DE5\u5927\u5B66
Absstract of: CN120392795A
The invention discloses application of a natural small molecule K252d in preparation of a medicine for treating inflammatory bowel disease and a preparation method of the medicine, and belongs to the field of biological medicine. K252d can remarkably promote mutual combination of MDM2-FOXP3, improve expression of FOXP3, promote differentiation of iTreg and enhance stability of FOXP3 and a Treg cell inhibition function, so that the effect of treating the inflammatory bowel disease is achieved. Compared with other treatment schemes in the prior art, the target enhancement path provided by the invention has the advantages that the off-target effect is remarkably reduced, and the toxic and side effects are reduced.
BOPI
Electronic site
